PDZK1 and plasma cell myeloma: PDZK1 acts as a tumor suppressor in gastric cancer and renal cancer, but in esophageal adenocarcinoma, breast cancer, and multiple myelomas (MMs), the overexpression of PDZK1 promotes cancer development or drug resistance (71–73).